Učitavanje...
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update
Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive n...
Spremljeno u:
| Izdano u: | Leuk Lymphoma |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4840280/ https://ncbi.nlm.nih.gov/pubmed/26592922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1099647 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|